The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
Open accessAbstract
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A–D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition in mild to moderate Alzheimer’s disease (A), memantine for moderate to severe Alzheimer’s disease (A) and combination therapy (cholinesterase inhibitors and memantine) may be beneficial (B). Drugs should not be stopped just because dementia severity increases (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer’s disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson’s disease dementia and dementia with Lewy bodies), and memantine may be helpful (A). No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B). Early evidence suggests multifactorial interventions may have potential to prevent or delay the onset of dementia (B). Though the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in those with or at high risk of Alzheimer’s disease are in progress. Though results of pivotal studies in early (prodromal/mild) Alzheimer’s disease are awaited, results to date in more established (mild to moderate) Alzheimer’s disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–241 of 241
McCarney, R., Fisher, P., Iliffe, S., van Haselen, R. A., Griffin, M., van der Meulen, J., & Warner, J. P. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2055 · Cited by 81
von Gunten, A., Schlaefke, S., & Überla, K. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1066513 · Cited by 77
Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives
Baskys, A., & Cheng, J. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.002 · Cited by 76
Stimulant Treatment of Frontotemporal Dementia in 8 Patients
Huey, E. D., Garcia, C., Wassermann, E. M., Tierny, M. C., & Grafman, J. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1219a · Cited by 73
Memantine for Behavioral Disturbances in Frontotemporal Dementia: A Case Series
Swanberg, M. (2007) · Alzheimer Disease and Associated Disorders · doi:10.1097/wad.0b013e318047df5d · Cited by 72
Mecocci, P., Bladström, A., & Stender, K. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2226 · Cited by 72
New approaches to the treatment of frontotemporal lobar degeneration
Vossel, K. A., & Miller, B. L. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328318444d · Cited by 71
Improving end-of-life care for people with dementia
Sampson, E. L., Burns, A. S., & Richards, M. A. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.097030 · Cited by 70
Self-citationRichard, E., Kuiper, R., Dijkgraaf, M. G. W., van Gool, W. A., & for the Evaluation of Vascular care in Alzheimer's disease Study Group (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02217.x · Cited by 68
Comprehensive treatment of dementia with Lewy bodies
Boot, B. P. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0128-z · Cited by 67
Cognitive Decline in Older Persons Initiating Anticholinergic Medications
Shah, R. C., Janos, A. L., Kline, J. E., Yu, L., Leurgans, S. E., Wilson, R. S., Wei, P., Bennett, D. A., Heilman, K. M., & Tsao, J. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064111 · Cited by 67
Colloby, S. J., Firbank, M., Pakrasi, S., Lloyd, J. J., Driver, I., McKeith, I. G., Williams, E. D., & O'Brien, J. T. (2008) · International Psychogeriatrics · doi:10.1017/s1041610208007709 · Cited by 67
Self-citationAbsence of cholinergic deficits in “pure” vascular dementia
Perry, E. K., Ziabreva, I., Perry, R., Aarsland, D., & Ballard, C. G. (2005) · Neurology · doi:10.1212/01.wnl.0000148591.63727.80 · Cited by 63
Amyloid imaging for dementia in clinical practice
O'Brien, J. T., & Herholz, K. (2015) · BMC Medicine · doi:10.1186/s12916-015-0404-6 · Cited by 62
Self-citationMori, E., Ikeda, M., Nagai, R., Matsuo, K., Nakagawa, M., & Kosaka, K. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0081-2 · Cited by 59
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Huperzine A for vascular dementia
Hao, Z., Liu, M., Liu, Z., & Lu, D. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007365.pub2 · Cited by 54
Wang, B., Wang, B., Song, Y., Qi, H., Rong, Z.-X., Wang, B., Zhang, L., & Chen, H.-Z. (2010) · Pharmacopsychiatry · doi:10.1055/s-0029-1242817 · Cited by 54
Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis
Bhasin, M., Rowan, E. N., Edwards, K. R., & McKeith, I. G. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1759 · Cited by 53
Self-citationWilcock, J., Iliffe, S., Griffin, M., Jain, P. N., Thuné‐Boyle, I., Lefford, F., & Rapp, D. (2013) · Trials · doi:10.1186/1745-6215-14-397 · Cited by 53
the CAREDEM team, Bamford, C., Poole, M., Brittain, K., Chew-Graham, C., Fox, C., Iliffe, S., Manthorpe, J., & Robinson, L. (2014) · BMC Health Services Research · doi:10.1186/s12913-014-0549-6 · Cited by 53
Self-citationPrevention of Alzheimer's disease
Szekely, C. A., Breitner, J. C. S., & Zandi, P. P. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797944 · Cited by 51
Wilkinson, D. G., Schindler, R. J., Schwam, E. M., Waldemar, G., Jones, R. W., Gauthier, S. G., López, O. L., Cummings, J. L., Xu, Y., & Feldman, H. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000241877 · Cited by 48
Self-citationVickrey, B. G., Mittman, B. S., Connor, K. I., Pearson, M. L., Della Penna, R. D., Ganiats, T. G., DeMonte, R. W., Chodosh, J., Cui, X., Vassar, S., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00004 · Cited by 44
Passmore, A. P., Bayer, A. J., & Steinhagen‐Thiessen, E. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.11.017 · Cited by 43
Mukadam, N., Livingston, G., Rantell, K. R., & Rickman, S. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004119 · Cited by 42
Self-citationCholine Acetyltransferase Activity in Vascular Dementia and Stroke
Sharp, S. I., Francis, P. T., Elliott, M. S. J., Kalaria, R. N., Bajic, N., Hortobágyi, T., & Ballard, C. G. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000239235 · Cited by 42
Pardini, M., Serrati, C., Guida, S., Mattei, C., Abate, L., Massucco, D., Sassos, D., Amore, M., Krüeger, F., Cocito, L., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000369811 · Cited by 41
Pathology in Primary Progressive Aphasia Syndromes
Harris, J., & Jones, M. S. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0466-4 · Cited by 41
Self-citationEducation and Use of Dementia Drugs: A Register-Based Study of Over 600,000 Older People
Johnell, K., Weitoft, G. R., & Fastbom, J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000111534 · Cited by 40
Management of dementia with a cerebrovascular component
Bocti, C., Black, S. E., & Frank, C. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.07.009 · Cited by 30
Trial Designs and Outcomes in Dementia Therapeutic Research
Rockwood, K. J., & Gauthier, S. G. (2005) · CRC Press eBooks · doi:10.4324/9780203340653 · Cited by 28
Current Concepts in Vascular Cognitive Impairment and Pharmacotherapeutic Implications
Rojas‐Fernandez, C. H., & Moorhouse, P. A. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l703 · Cited by 27
Antidementia drugs: Prescription by level of cognitive impairment or by socio-economic group?
Cooper, C., Blanchard, M. R., Selwood, A., & Livingston, G. (2010) · Aging & Mental Health · doi:10.1080/13607860902918256 · Cited by 26
Self-citationDifferent Responses to Rivastigmine in Subcortical Vascular Dementia and Multi-Infarct Dementia
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Pizzolato, G. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317507312558 · Cited by 26
Primary vs. Subspecialty Care: A Structured Follow-Up of Dementia Patients and Their Caregivers
Aupperle, P. M., & Coyne, A. C. (2000) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200005000-00012 · Cited by 25
Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistence
Yamamura, K., Suzuki, Y., Umegaki, Shigeno, K., Matsushita, R., Sai, Y., Miyamoto, K.-I., & Yamada, K. (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s34984 · Cited by 19
The inclusion of cognition in vascular risk factor clinical practice guidelines
Middleton, L. E., Rockwood, Moorhouse, Skoog, & Black (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6738 · Cited by 15
Aupperle, P. M., MacPhee, E. R., Coyne, A. C., Blume, J., & Sanchez, B. (2003) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988702250507 · Cited by 15
Wilcock, G. K., Black, S. E., Balch, A. H., Amato, D. A., Beelen, A. P., Schneider, L. S. S., Green, R. C., Swabb, E. A., & Zavitz, K. H. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.220 · Cited by 14
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationThe projected effect of risk factor reduction on Alzheimer's disease prevalence
Barnes, D. E., & Yaffe, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70072-2 · Cited by 2,666
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Metadata
- Authors
- O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., Sampson, E. L., Taylor, J.-P., Thomas, A., & Burns, A.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-01-20
- Volume
- 31
- Issue
- 2
- Pages
- 147-168
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2090156874
- Cited by
- 354
- References
- 241
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.